Trials that use: Covariate adjustment
119 results
- ABCSG-18Independent statistical analysis of ABCSG-18, a randomized phase 3 trial of denosumab in patients with breast cancer receiving aromatase inhibitor therapy, including trial design, fracture, bone mineral density, disease-free survival, bone metastases-free…
- ACTG A5279Independent statistical analysis of ACTG A5279 (NCT01404312), a randomized phase 3 trial comparing a rifapentine-plus-isoniazid regimen with an isoniazid regimen for tuberculosis prevention in people with HIV.
- ADRIATICIndependent statistical analysis of the phase 3 ADRIATIC trial of durvalumab, tremelimumab, and placebo in limited-stage small-cell lung cancer after concurrent chemoradiation, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, and…
- AGO-OVAR 12Independent statistical analysis of AGO-OVAR 12 (NCT01015118), a randomized phase 3 trial of nintedanib or placebo with paclitaxel and carboplatin in first-line ovarian cancer, including progression-free survival, overall survival, response, quality of…
- AIM-HIGHIndependent statistical analysis of AIM-HIGH, the randomized phase 3 trial of extended-release niacin plus simvastatin versus placebo plus simvastatin for prevention of vascular events, including its time-to-event endpoints, Cox model, hazard ratios,…
- ALEXIndependent statistical analysis of the phase 3 ALEX trial comparing alectinib with crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer, including progression-free survival, CNS progression, overall survival, response, quality-of-life endpoints, and…
- ALTTOIndependent statistical analysis of the phase 3 ALTTO trial of lapatinib and trastuzumab in breast neoplasms, covering randomized trial design, disease-free survival, overall survival, recurrence endpoints, safety, and time-to-event methodology.
- APACTIndependent statistical analysis of APACT, the randomized phase 3 trial of nab-paclitaxel and gemcitabine versus gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer.
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- BEAUTIFULIndependent statistical analysis of the phase 3 BEAUTIFUL trial of ivabradine versus placebo in patients with stable coronary artery disease and left ventricular systolic dysfunction, including its composite primary endpoint, time-to-event methods,…
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CheckMate-037Independent statistical analysis of CheckMate-037, a randomized phase 3 trial of BMS-936558 (nivolumab) versus Investigator's Choice in unresectable or metastatic melanoma.
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…
- COMBI-ADAn independent statistical analysis of the phase 3 COMBI-AD trial of dabrafenib with trametinib in high-risk BRAF V600 mutation-positive melanoma, including trial design, relapse-free survival, secondary time-to-event analyses, statistical methods, and interpretation.
- COMET-PEAKIndependent statistical analysis of COMET-PEAK, the randomized phase 2 trial evaluating second-generation sotrovimab material in non-hospitalized participants with mild to moderate COVID-19, including viral-load, pharmacokinetic, ANCOVA, ANOVA, safety, and statistical interpretation.
- COMPARZIndependent statistical analysis of the COMPARZ phase 3 trial comparing pazopanib with sunitinib in locally advanced and/or metastatic renal cell carcinoma, including its progression-free survival endpoint, non-inferiority framework, Cox model, and reported…
- CRESTIndependent statistical analysis of CREST (NCT00004732), a randomized double-masked trial comparing carotid endarterectomy with carotid artery stenting for patients with carotid stenosis.
- DAPA-CKDIndependent statistical analysis of the randomized phase 3 DAPA-CKD trial evaluating dapagliflozin versus placebo for renal and cardiovascular outcomes in patients with chronic kidney disease.
- DAPA-HFIndependent statistical analysis of the DAPA-HF phase 3 trial evaluating dapagliflozin in patients with chronic heart failure with reduced ejection fraction, including trial design, endpoints, Cox models, win ratio, rate ratio, results,…
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DISCOVERIndependent statistical analysis of the DISCOVER phase 3 trial evaluating F/TAF versus F/TDF for HIV-1 pre-exposure prophylaxis, including non-inferiority testing, rate-ratio analysis, BMD, renal biomarkers, and statistical methodology.
- EINSTEIN-DVTIndependent statistical analysis of EINSTEIN-DVT, a randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with venous thrombosis, including its non-inferiority analysis, Cox model, hazard ratio, confidence interval,…
- EINSTEIN-PEIndependent statistical analysis of EINSTEIN-PE, the randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with acute symptomatic pulmonary embolism, including non-inferiority methodology, Cox analysis, hazard ratios, bleeding,…
- ELIXAIndependent statistical analysis of the ELIXA phase 3 trial of lixisenatide versus placebo in patients with acute coronary syndrome and type 2 diabetes, including its time-to-event endpoint, non-inferiority framework, hazard ratio, confidence…
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMPEROR-PreservedA detailed statistical analysis of EMPEROR-Preserved, the randomized phase 3 trial of 10 mg empagliflozin versus placebo in patients with heart failure, including time-to-event outcomes, Cox models, recurrent-event analysis, MMRM, and interpretation.
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- EORTC 18071Independent statistical analysis of EORTC 18071, a randomized phase 3 trial of ipilimumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, distant metastasis-free survival, overall survival, and…
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- FLAMINGOComplete statistical analysis of the FLAMINGO phase 3 trial comparing dolutegravir with darunavir/ritonavir, each combined with dual NRTIs in ART-naive participants with HIV-1 infection.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GOG-0252Independent statistical analysis of GOG-0252, a randomized phase 3 trial of bevacizumab with intravenous or intraperitoneal chemotherapy in patients with stage II-III ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- GOLDEN-3Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint, MMRM methodology, multiplicity control, confidence intervals, and reported results.
- GOLDEN-4Independent statistical analysis of GOLDEN-4, a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its MMRM methodology, primary FEV1 results, multiplicity approach, safety data, and statistical interpretation.
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- KEYNOTE-024Independent statistical analysis of KEYNOTE-024 (NCT02142738), including randomized trial design, progression-free survival, overall survival, objective response rate, Cox modeling, confidence intervals, and statistical interpretation.